This trial studies how well an additional PET/CT scan immediately after injection of an imaging drug works in imaging patients who are suspected of having cancer. As part of standard of care, a PET/CT scan usually occurs about 1 hour after the imaging drug is injected and accumulates in different parts of the body. Performing an additional PET/CT scan during the first hour following imaging drug injection, may provide researchers with more information.
Additional locations may be listed on ClinicalTrials.gov for NCT04283552.
See trial information on ClinicalTrials.gov for a list of participating sites.
PRIMARY OBJECTIVES:
I. Assess the technical feasibility of dynamic, whole-body multiparametric positron emission tomography (PET) imaging.
II. Assess the quantitative and clinical impacts of a novel approach to PET data motion correction (OncoFreeze), relative to more conventional static and respiratory-gated PET images.
III. Quantify the test-retest repeatability of quantitative metrics extracted from dynamic PET images.
IV. Comparison of the early and late Patlak images to determine the optimal post-injection time period for dynamic PET imaging for Patlak analysis.
OUTLINE:
Patients receive standard of care fludeoxyglucose F 18 intravenously (IV) and undergo dynamic PET/computed tomography (CT) scan over 60 minutes. After completion of dynamic PET/CT scan, patients undergo standard of care PET/CT scan over 30 minutes.
REPEATABILITY COHORT: Within 7 days, patients receive fludeoxyglucose F 18 or 68Ga- DOTA-0-Tyr3-Octreotate (DOTATATE) and undergo additional PET/CT imaging.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationSiteman Cancer Center at Washington University
Principal InvestigatorRichard L Wahl
